Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,34163139,flow rate,"The column was Acquity UPLC BEH C18 column and the mobile phase was acetonitrile-formic acid with gradient mode, and the flow rate was set at 0.4 mL/min.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),[ml] / [min],0.4,59672,DB01209,Dezocine
,34163139,m/,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,381.10,59673,DB01209,Dezocine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,246.20,59674,DB01209,Dezocine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,147.00,59675,DB01209,Dezocine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,201.10,59676,DB01209,Dezocine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,94.90,59677,DB01209,Dezocine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,326.10,59678,DB01209,Dezocine
,34163139,m/z,"Under the positive ion mode, CEL, DEZ, DEX and Midazolam (internal standard, IS) were monitored by multiple reaction monitoring (MRM) as the following mass transition pairs: m/z 381.10→282.10 for CEL, m/z 246.20→147.00 for DEZ, m/z 201.10→94.90 for DEX, and m/z 326.10→291.10 for IS.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),,291.10,59679,DB01209,Dezocine
more,34163139,extraction recovery,"The extraction recovery was more than 79%, and the matrix effect was around 100%.","Simultaneous Determination of Celecoxib, Dezocine and Dexmedetomidine in Beagle Plasma Using UPLC-MS/MS Method and the Application in Pharmacokinetics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34163139/),%,79,59680,DB01209,Dezocine
less,7650230,t1/2 alpha,"After these single doses, dezocine was very rapidly distributed (mean t1/2 alpha less than 2 minutes), and then rather rapidly eliminated (mean t1/2 beta about 4 hours); the apparent volume of distribution was large (mean Vz beta about 6 L/kg) as was the total clearance (mean CL about 1.5 L/h/kg).",Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650230/),min,2,87776,DB01209,Dezocine
,7650230,t1/2 beta,"After these single doses, dezocine was very rapidly distributed (mean t1/2 alpha less than 2 minutes), and then rather rapidly eliminated (mean t1/2 beta about 4 hours); the apparent volume of distribution was large (mean Vz beta about 6 L/kg) as was the total clearance (mean CL about 1.5 L/h/kg).",Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650230/),h,4,87777,DB01209,Dezocine
,7650230,Vz beta,"After these single doses, dezocine was very rapidly distributed (mean t1/2 alpha less than 2 minutes), and then rather rapidly eliminated (mean t1/2 beta about 4 hours); the apparent volume of distribution was large (mean Vz beta about 6 L/kg) as was the total clearance (mean CL about 1.5 L/h/kg).",Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650230/),[l] / [kg],6,87778,DB01209,Dezocine
,7650230,CL,"After these single doses, dezocine was very rapidly distributed (mean t1/2 alpha less than 2 minutes), and then rather rapidly eliminated (mean t1/2 beta about 4 hours); the apparent volume of distribution was large (mean Vz beta about 6 L/kg) as was the total clearance (mean CL about 1.5 L/h/kg).",Single- and multiple-dose pharmacokinetics of dezocine in patients with acute or chronic pain. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7650230/),[l] / [h·kg],1.5,87779,DB01209,Dezocine
,6126336,half-life,"In both species, the drug was rapidly distributed after intravenous administration and then eliminated with a mean half-life of 2.4 hr.",Pharmacokinetics of parenteral dezocine in rhesus monkeys and dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126336/),h,2.4,113555,DB01209,Dezocine
,6126336,Systemic clearance,"Systemic clearance was 54.8 +/- 8.6(SD) and 65.8 +/- 14.0(SD) ml/min/kg in the rhesus monkey and dog, respectively.",Pharmacokinetics of parenteral dezocine in rhesus monkeys and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126336/),[ml] / [kg·min],54.8,113556,DB01209,Dezocine
,6126336,Systemic clearance,"Systemic clearance was 54.8 +/- 8.6(SD) and 65.8 +/- 14.0(SD) ml/min/kg in the rhesus monkey and dog, respectively.",Pharmacokinetics of parenteral dezocine in rhesus monkeys and dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6126336/),[ml] / [kg·min],65.8,113557,DB01209,Dezocine
,3709625,Elimination half-life,"Elimination half-life following 5, 10, and 20 mg IV doses averaged 2.6-2.8 h, and was independent of dose.","Pharmacokinetics of dezocine, a new analgesic: effect of dose and route of administration. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709625/),h,2.6-2.8,153752,DB01209,Dezocine
,3709625,bioavailability,"After Deltoid IM injection, dezocine was rapidly absorbed (peak level: 0.6 h after dose), with bioavailability 97%.","Pharmacokinetics of dezocine, a new analgesic: effect of dose and route of administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3709625/),%,97,153753,DB01209,Dezocine
